Gilead set to benefit from Tamiflu orders
On April 30, in what was virtually her first decision since being confirmed to office, the USA's new Health and Human Services Secretary, Kathleen Sebelius, said that the government would quickly look to re-stock the 12 million doses of Tamiflu (oseltamivir) released earlier in the week to combat the H1N1 (swine flu) virus.
Over the past few years the Centers for Disease Control has kept a stockpile of about 50 million doses of the antiviral drug, Tamiflu (oseltamivir), on hand specifically to combat pandemic spreading of the flu virus. The policy came into effect on fears that the H5N1 (avian flu) virus was becoming a global pandemic in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze